Video

Dr. Lentzsch on How Patient Age Informs Treatment Decisions in Multiple Myeloma

Suzanne Lentzsch, MD, discusses how patient age informs treatment decisions in multiple myeloma.

Suzanne Lentzsch, MD, professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, College of Physicians and Surgeons of Columbia University, Columbia University Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital, discusses how patient age informs treatment decisions in multiple myeloma.

Age is a significant determinant of treatment in multiple myeloma, Lentzsch says. For example, a younger, transplant-eligible patient will have a significantly different treatment course compared with a patient over the age of 80 years.

Ultimately, the goal of care in younger patients is to prolong life, so aggressive treatment regimens with associated toxicities can be considered to ensure patients obtain the deepest remission possible, Lentzsch says. Although remission is a goal of therapy in older patients, it is equally important to maximize quality of life for these patients, Lentzsch concludes.

Related Videos
Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
4 experts are featured in this series.
4 experts are featured in this series.
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center